KRAS and non-small cell lung carcinoma: Garsorasib demonstrated 40.5% ORR, 91.9% DCR, and 8.2 months median PFS in a phase I trial of patients in China with locally advanced or metastatic KRAS G12C-mutant NSCLC who were refractory to or intolerant of standard chemoimmunotherapy [35].